REPONEX PHARMACEUTICALS A/S: Financial statements 2023
CVR: 30082346
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
REPONEX PHARMACEUTICALS A/S (CVR 30082346) has filed annual accounts for 2023. In 2023, the company reported a gross profit of EUR 0 and a net result of EUR -14,346,000 compared with DKK -10,209,830 the year before. Equity in the 2023 report amounted to EUR 16,757,000. The solvency ratio was 77.4%.
- Revenue
- EUR 0
- Gross Profit
- EUR 0
- Profit/Loss
- EUR -14,346,000
- Equity
- EUR 16,757,000
- Total Assets
- EUR 21,662,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | 0 EUR | 0 EUR | -14.3M EUR | 16.8M EUR | - |
| 2022 | - | - | -10.2M | 17.4M | - |
| 2021 | 0 | 0 | -9.9M | 27.4M | - |
| 2020 | 0 | 0 | -1.5M | 13.4M | - |
| 2019 | 0 | 0 | -1.9M | 14.9M | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of June 15, 2023, Peter Mørch Eriksen has left the board of directors of REPONEX PHARMACEUTICALS A/S.
As of June 14, 2023, Thomas Kaas Selsø is registered as adm. dir. of REPONEX PHARMACEUTICALS A/S.
As of June 14, 2023, Sigbjørn Georg Nielsen Kjærgård has stepped down as adm. dir. of REPONEX PHARMACEUTICALS A/S.
As of June 13, 2023, Thomas Kaas Selsø has stepped down as director of REPONEX PHARMACEUTICALS A/S.
REPONEX PHARMACEUTICALS A/S has published its annual report for 2022. The net result was DKK -10,209,830.
As of April 27, 2023, A/S PSE 17 NR. 1056 has been appointed auditor of REPONEX PHARMACEUTICALS A/S.
As of April 27, 2023, Grant Thornton, Godkendt Revisionspartnerselskab has stepped down as auditor of REPONEX PHARMACEUTICALS A/S.
As of April 27, 2023, Lisbeth Thyregod has left the board of directors of REPONEX PHARMACEUTICALS A/S.
As of April 27, 2023, Mette Zacho has left the board of directors of REPONEX PHARMACEUTICALS A/S.
As of March 31, 2023, Peter Mørch Eriksen has joined the board of directors of REPONEX PHARMACEUTICALS A/S.
About REPONEX PHARMACEUTICALS A/S
REPONEX PHARMACEUTICALS A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2006. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named REPONEX PHARMACEUTICALS ApS and TRIFOILIUM ApS. The management consists of Christian Henrik Tange. The board consists of Christian Vinding Thomsen (chair), Troels Peter Troelsen and Charlotte Pahl. The company is owned by Pharma Equity Group A/S. The company has 2 employees (2026). In 2025, the company reported a gross profit of DKK 0 and a net result of DKK -6,570,000 compared with DKK -11,943,000 the year before. Equity in the 2025 report amounted to DKK 4,645,000.